Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

What happened: The fair value estimate for Summit Therapeutics moved from about US$29.21 to about US$30.07 per share, tied to the US$2b AstraZeneca funding and expectations around HARMONi-3 lung cancer data. Key numbers: Fair value about US$30.07 per share, previously about US$29.21. Why it matters: Citi says the deal removes a financing overhang, while Bernstein and Leerink moved to Market Perform as pricing is seen closer to intrinsic value. Barclays flags execution risk beyond squamous lung cancer, and H.C. Wainwright and Jefferies point to timing and data risk on later readouts. Market: -4.8% today ($14.63), -16.5% YTD, 0.6x vol — as of 22:46 UTC Verified: Q3_2026 (Oct 19) EPS $-0.22 vs $-0.21 est, -4.9% miss; next print ~Jan 18

The fair value estimate for Summit Therapeutics moved from about US$29.21 to about US$30.07 per share, tied to the US$2b AstraZeneca funding and expectations around HARMONi-3 lung cancer data.

Citi says the deal removes a financing overhang, while Bernstein and Leerink moved to Market Perform as pricing is seen closer to intrinsic value. Barclays flags execution risk beyond squamous lung cancer, and H.C. Wainwright and Jefferies point to timing and data risk on later readouts. Market: -4.8% today ($14.63), -16.5% YTD, 0.6x vol — as of 22:46 UTC Verified: Q3_2026 (Oct 19) EPS $-0.22 vs $-0.21 est, -4.9% miss; next print ~Jan 18